EA201591798A1 - Композиции и способы усиления иммунного ответа на кишечные патогены - Google Patents

Композиции и способы усиления иммунного ответа на кишечные патогены

Info

Publication number
EA201591798A1
EA201591798A1 EA201591798A EA201591798A EA201591798A1 EA 201591798 A1 EA201591798 A1 EA 201591798A1 EA 201591798 A EA201591798 A EA 201591798A EA 201591798 A EA201591798 A EA 201591798A EA 201591798 A1 EA201591798 A1 EA 201591798A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptide
methods
immune response
compositions
enhancing immune
Prior art date
Application number
EA201591798A
Other languages
English (en)
Other versions
EA033538B1 (ru
Inventor
Лиза Билк
Шеррилл Лейтон
Билли Харджис
Нейл Р. Памфорд
Оливия Б. Фолкнер
Люк Бергман
Даад Аби-Гханем
Original Assignee
Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас
Дзе Тексас Эй Энд Эм Юниверсити Систем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас, Дзе Тексас Эй Энд Эм Юниверсити Систем filed Critical Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас
Publication of EA201591798A1 publication Critical patent/EA201591798A1/ru
Publication of EA033538B1 publication Critical patent/EA033538B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к вакцинным векторам, способным вызывать иммунный ответ на кишечные бактерии, и к способам их применения. Вакцинные векторы включают полинуклеотид, кодирующий полипептид PAL. Полипептид PAL может экспрессироваться на поверхности вакцинного вектора. Вакцинный вектор также может включать второй полипептид, кодирующий иммуностимулирующий полипептид, такой как полипептид CD154 или полипептид HMGB1.
EA201591798A 2013-03-15 2014-03-14 Композиции и способы усиления иммунного ответа на кишечные патогены EA033538B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790301P 2013-03-15 2013-03-15
PCT/US2014/027416 WO2014152508A1 (en) 2013-03-15 2014-03-14 Compositions and methods of enhancing immune responses to enteric pathogens

Publications (2)

Publication Number Publication Date
EA201591798A1 true EA201591798A1 (ru) 2016-06-30
EA033538B1 EA033538B1 (ru) 2019-10-31

Family

ID=51581229

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591798A EA033538B1 (ru) 2013-03-15 2014-03-14 Композиции и способы усиления иммунного ответа на кишечные патогены

Country Status (18)

Country Link
US (3) US10376571B2 (ru)
EP (2) EP2968423A4 (ru)
JP (1) JP6530742B2 (ru)
KR (1) KR102239207B1 (ru)
CN (1) CN105142653B (ru)
AR (1) AR095313A1 (ru)
AU (1) AU2014239557B2 (ru)
BR (1) BR112015023024B1 (ru)
CA (1) CA2906079C (ru)
CL (2) CL2015002741A1 (ru)
EA (1) EA033538B1 (ru)
HK (1) HK1219045A1 (ru)
MX (1) MX2015012855A (ru)
MY (1) MY173901A (ru)
PH (1) PH12015502135B1 (ru)
SG (1) SG11201507421XA (ru)
WO (1) WO2014152508A1 (ru)
ZA (1) ZA201506466B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CA3156538C (en) * 2007-11-01 2023-12-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
EP2956165B1 (en) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
EP2968423A4 (en) * 2013-03-15 2016-11-09 Univ Arkansas COMPOSITIONS AND METHODS FOR INCREASING IMMUNE REACTIONS AGAINST ENTERAL PATHOGENES
EP3452069A4 (en) * 2016-05-03 2020-02-12 The Board of Trustees of the University of Arkansas Yeast vaccine vector with immunostimulating and antigenic polypeptides and method for using them
CN106124772B (zh) * 2016-06-15 2018-05-04 金华职业技术学院 一种基于omp18检测空肠弯曲菌的elisa检测试剂盒及其应用
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018226887A1 (en) * 2017-06-07 2018-12-13 Spark Therapeutics, Inc. ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
WO2021242798A1 (en) * 2020-05-26 2021-12-02 Synlogic Operating Company, Inc. Surface display of proteins on recombinant bacteria and uses thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ285118B6 (cs) 1991-03-05 1999-05-12 The Wellcome Foundation Limited Exprese rekombinačních proteinů v oslabených bakteriích
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
CA2121798C (en) 1991-10-25 2007-07-24 Richard J. Armitage Novel cytokine
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
AU683221B2 (en) 1992-09-04 1997-11-06 University Of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
ES2179187T3 (es) 1995-03-01 2003-01-16 Immunex Corp Oriteuba qye se yba a cd40 para estimular una respuesta inmune.
IL122174A (en) 1995-06-07 2004-07-25 Immunex Corp DNA encoding the CD40L mutine and CD40L polypeptide encoded by the above DNA
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
IL136731A0 (en) 1997-12-19 2001-06-14 Immunex Corp Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
ATE403728T1 (de) 1998-09-04 2008-08-15 Emergent Product Dev Uk Ltd Attenuierte salmonella spi2 mutante als antigen- träger
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1173589A1 (en) 1999-04-16 2002-01-23 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
CA2382221A1 (en) * 1999-08-20 2001-03-01 H. Shaw Warren Outer membrane protein a, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis
EP1246643A4 (en) 1999-10-14 2005-05-11 Jeffery A Ledbetter DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN
DE60011560T2 (de) 1999-12-28 2005-08-18 Akzo Nobel N.V. Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
WO2001054472A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
ATE412427T1 (de) 2000-02-02 2008-11-15 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
CA2402252A1 (en) 2000-03-17 2001-09-27 Pharmacia & Upjohn Company Salmonella vaccine materials and methods
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
EP1299115A2 (en) 2000-06-26 2003-04-09 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
WO2002036769A2 (en) 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
AU2002309829B2 (en) 2001-05-15 2007-08-23 The Feinstein Institute For Medical Research Use of HMG fragment as anti-inflammatory agents
DE60233231D1 (de) 2001-05-15 2009-09-17 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
WO2003051383A2 (de) 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
DE60227285D1 (de) 2001-12-21 2008-08-07 Immunex Corp Rekombinante polypeptide
WO2003067991A1 (en) 2002-02-13 2003-08-21 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
ATE556596T1 (de) 2002-04-15 2012-05-15 Univ St Louis Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
NZ540067A (en) 2002-11-20 2007-05-31 Critical Therapeutics Inc A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
JP2006506441A (ja) 2002-11-20 2006-02-23 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト 免疫応答を増大させるためのｈｍｇｂポリペプチドの使用
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
EP1673389A2 (en) 2003-10-10 2006-06-28 Xencor Inc. Novel variants of cd40l protein
AU2004291213B2 (en) 2003-11-21 2011-09-08 Ace Biosciences A/S Surface-located campylobacter jejuni polypeptides
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
EP1720905A2 (en) 2003-12-11 2006-11-15 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
WO2005103073A2 (en) 2004-04-27 2005-11-03 Intercell Ag Td antigens
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
EP1768698A4 (en) 2004-06-17 2009-01-28 Medimmune Inc IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES
WO2006012373A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
DE602005025005D1 (de) 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
GB0423681D0 (en) 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
WO2006130525A2 (en) 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
EP1909834A2 (en) 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
CA2625506C (en) 2005-10-07 2014-06-10 Proyecto De Biomedicina Cima, S.L. Immuno-stimulant combination for prophylaxis and treatment of hepatitis c
JP2009514536A (ja) 2005-11-07 2009-04-09 シドニー キンメル キャンサー センター Ｃｄ４０リガンド融合蛋白質ワクチン
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
WO2007130725A2 (en) 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
CU23576A1 (es) 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
WO2007106073A2 (en) 2006-03-02 2007-09-20 University Of Massachusetts Modified pathogens for use as vaccines
CN101064542B (zh) 2006-04-30 2010-12-08 中兴通讯股份有限公司 Mimo ofdm系统中发射天线选择与自适应调制方法
PL2059256T3 (pl) * 2006-08-11 2017-02-28 Life Sciences Research Partners Vzw Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
CA2659552A1 (en) * 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
MY183797A (en) 2006-09-18 2021-03-16 Univ Arkansas Compositions and methods of enhancing immune responses
US20100292309A1 (en) 2007-03-08 2010-11-18 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
CA2704457A1 (en) 2007-10-30 2009-05-07 Walter Bottje Compositions and methods of enhancing immune responses to flagellated bacterium
CA3156538C (en) 2007-11-01 2023-12-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
EP2471553A4 (en) * 2009-06-26 2013-08-28 Vectorite Biomedica Inc IMMUNOGENIC COMPOSITION WITH PEPTIDES FROM CYTOMEGALOVIRUS AND THEIR USE
GB0917002D0 (en) * 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
CA2787661C (en) 2010-01-21 2021-10-12 The Board Of Trustees Of The University Of Arkansas Vaccine vectors and methods of enhancing immune responses
CA2800830C (en) 2010-06-09 2020-09-08 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
US20140328815A1 (en) 2011-11-11 2014-11-06 Nutrition Physiology Company, Llc Lactic Acid Bacteria And Their Use As Dietary Supplementals For Poultry
CN104159601B (zh) 2012-02-01 2017-05-24 代表亚利桑那大学的亚利桑那董事会 弯曲杆菌属免疫原性组合物及其用途
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EA031234B1 (ru) 2012-10-29 2018-12-28 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Вакцина с адъювантом на основе маннозилированного хитозана
EP2956165B1 (en) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
EP2968423A4 (en) * 2013-03-15 2016-11-09 Univ Arkansas COMPOSITIONS AND METHODS FOR INCREASING IMMUNE REACTIONS AGAINST ENTERAL PATHOGENES

Also Published As

Publication number Publication date
BR112015023024A2 (pt) 2017-11-14
NZ711761A (en) 2021-08-27
SG11201507421XA (en) 2015-10-29
KR20150130480A (ko) 2015-11-23
MX2015012855A (es) 2016-07-21
AU2014239557B2 (en) 2019-01-03
PH12015502135A1 (en) 2016-01-25
US20190351042A1 (en) 2019-11-21
BR112015023024B1 (pt) 2022-04-19
CA2906079C (en) 2022-08-23
HK1219045A1 (zh) 2017-03-24
PH12015502135B1 (en) 2016-01-25
EA033538B1 (ru) 2019-10-31
US10716840B2 (en) 2020-07-21
US20160038581A1 (en) 2016-02-11
KR102239207B1 (ko) 2021-04-09
CA2906079A1 (en) 2014-09-25
AU2014239557A2 (en) 2016-01-14
ZA201506466B (en) 2023-05-31
US11013792B2 (en) 2021-05-25
MY173901A (en) 2020-02-26
AU2014239557A1 (en) 2015-10-15
JP2016515133A (ja) 2016-05-26
US10376571B2 (en) 2019-08-13
CL2017002971A1 (es) 2018-03-16
CL2015002741A1 (es) 2016-02-12
CN105142653A (zh) 2015-12-09
US20200297832A1 (en) 2020-09-24
JP6530742B2 (ja) 2019-06-12
AR095313A1 (es) 2015-10-07
EP3578190A1 (en) 2019-12-11
CN105142653B (zh) 2019-11-15
EP2968423A4 (en) 2016-11-09
WO2014152508A1 (en) 2014-09-25
EP2968423A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
EA201591798A1 (ru) Композиции и способы усиления иммунного ответа на кишечные патогены
MX2018001213A (es) Nuevos metodos para inducir una respuesta inmunitaria.
EA202091039A1 (ru) Аденовирусные векторы и пути их применения
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2017077085A3 (en) Immunomodulatory antibodies
DK3275188T3 (da) Bevægelsesvektorafledning i videokodning
EA201790550A1 (ru) Способы и композиции для ослабления иммунных ответов к корректирущим ген вирусным трансферным векторам
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
IN2014KN03063A (ru)
MX2021008318A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EP3197490C0 (en) METHODS AND COMPOSITIONS FOR INTRA-NASAL IMMUNIZATION RECOMBINANT MVA ENCODING FLAGELLIN
MX2017002890A (es) Métodos y composiciones para potenciar respuestas inmunitarias.
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
HK1256033A1 (zh) 用於刺激免疫系統的肽
TN2014000518A1 (en) Reassortant btv and ahsv vaccines
EA201591488A1 (ru) Композиции и способы усиления иммунных ответов на eimeria или ограничения инфекции eimeria
EA201790057A1 (ru) Антитела-антагонисты к интерферону альфа и интерферону омега
MX2017008286A (es) Nuevos metodos para el despliegue de peptidos ciclicos en particulas de bacteriofagos.
MX2019006090A (es) Metodos para mejorar la respuesta inmune con everolimus, dactolisib o ambos.
EP3324963A4 (en) METHODS AND COMPOSITIONS FOR ENHANCING AN IMMUNE RESPONSE TO VACCINATION
MX2018001251A (es) Respuesta inmunitaria potenciada de las especies porcinas.
WO2016075305A3 (en) Peptides derived from acinetobacter baumannii and their use in vaccination
GB201120634D0 (en) Adjuvant polypeptide
IT201600116554A1 (it) Probiotic yeasts as novel vaccination vectors